Financhill
Back

Stoke Therapeutics Quote, Financials, Valuation and Earnings

Stoke Therapeutics Price Quote

$11.23
-0.63 (-5.31%)
(Updated: April 30, 2024 at 12:45 PM ET)

Stoke Therapeutics Key Stats

Buy
62
Stoke Therapeutics (STOK) is a Buy

Day range:
$11.50 - $12.73
52-week range:
$3.35 - $16.40
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
59.42
P/B ratio:
3.44%

Volume:
918.4K
Avg. volume:
2.3M
1-year change:
33.41%
Market cap:
$549.2M
Revenue:
$8.8M
EPS:
$-2.37

How Much Does Stoke Therapeutics Make?

Is Stoke Therapeutics Growing As A Company?

  • What Is Stoke Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is -0.14%
  • What Is Stoke Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Stoke Therapeutics Stock Price Performance

What Is Stoke Therapeutics 52-Week High & Low?

Stoke Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Stoke Therapeutics?

Is Stoke Therapeutics Cash Flow Positive?

  • What Is STOK Cash Flow From Operations?
    Cash flow from operations (TTM) is -$81.1M
  • What Is Stoke Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $53M
  • What Is Stoke Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $105.9M

Stoke Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    STOK return on invested capital is -56.81%
  • What Is Stoke Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -41.45%
  • What Is STOK Return On Equity?
    ROE is a measure of profitability and is -56.81%

Stoke Therapeutics Earnings Date & Stock Price

Stoke Therapeutics Competitors

  • Who Are Stoke Therapeutics's Competitors?
    Below is a list of companies who compete with Stoke Therapeutics or are related in some way:
    • Actinium Pharmaceuticals Inc (ATNM)
    • Fate Therapeutics Inc (FATE)
    • iBio Inc (IBIO)
    • Lixte Biotechnology Holdings Inc (LIXT)
    • NeuBase Therapeutics Inc (NBSE)

Stoke Therapeutics Dividend Yield

Data Unavailable

Stoke Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 4.32%
Revenue: -14.26% -13.04%

Analyst Recommendations

Buy Recommendations: 6
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 22.29
Upside from Last Price: 87.91%

Major Shareholders

  • How many STOK shares are owned by institutional investors?
    63.8M STOK shares are owned by institutional investors
  • How many STOK shares are owned by insiders?
    573.3K STOK shares are owned by insiders